Morgan Stanley’s Artiva Biotherapeutics ARTV Stock Holding History

Morgan Stanley’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$105K	Sell	16,377 -10,695	-40%	-$52.9K	﹤0.01%	6132
2025 Q4	$116K	Sell	27,072 -15,757	-37%	-$59.5K	﹤0.01%	6127
2025 Q3	$123K	Sell	42,829 -3,418	-7%	-$9.15K	﹤0.01%	6064
2025 Q2	$69.8K	Buy	46,247 +18,427	+66%	+$38.7K	﹤0.01%	6251
2025 Q1	$83.5K	Sell	27,820 -9,467	-25%	-$51.1K	﹤0.01%	6097
2024 Q4	$376K	Sell	37,287 -2,666	-7%	-$32K	﹤0.01%	5545
2024 Q3	$617K	Buy	+39,953	New	+$463K	﹤0.01%	5304

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCM

Revelation Capital Management Sausalito, California $67.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Morgan Stanley's ARTV Position: Q1 2026 in Review

Morgan Stanley reduced its Artiva Biotherapeutics (ARTV) stake by 40% in Q1 2026, selling an estimated $52.9K and leaving 16,377 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #6132.

Morgan Stanley first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $617K in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

Morgan Stanley held 16,377 shares of Artiva Biotherapeutics worth $105K as of Q1 2026.
Morgan Stanley sold 10,695 Artiva Biotherapeutics shares in Q1 2026, an estimated $52.9K.
Artiva Biotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6132 holding.
Morgan Stanley first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
Morgan Stanley's Artiva Biotherapeutics position peaked at $617K in Q3 2024.
40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.